前苏联专利SU1551248A3 Method of producing 4-pyridon-derivatives or their pharmaceutically aceeptable additive salts with i

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
4-Pyridone derivatives of the formula …<IMAGE>… in which… R1 denotes methylamino, 4-fluorophenyl or 2,4-difluorophenyl, R2 denotes hydrogen or a sulphur atom which is bonded to the ring nitrogen via an ethylene bridge, X denotes hydrogen or a physiologically acceptable ester group and Y denotes a base of the formula IIa or IIb of the formula sheet, in which R3 represents hydrogen, lower alkyl, benzyl, formyl, acetonyl or a radical of the formula III of the formula sheet, and addition salts of compounds of the formula I with pharmaceutically acceptable inorganic or organic acids or bases and/or their hydrates, are used as agents having antibacterial activity.
公开号:SU1551248A3
申请号:SU874203001
申请日:1987-07-03
公开日:1990-03-15
发明作者:Заутер Фритц；Йордис Ульрих；Рудольф Манфред；ВИЗЕР Йозеф；Бауманн Карл
申请人:Хеми Линц Аг (Фирма)；
IPC主号:

专利说明:

This invention relates to a process for the preparation of novel 4-pyridone derivatives with antibacterial action.
The aim of the invention is to obtain new antibacterial more effective 4-pyridone derivatives than the known structural analogues of the same effect.
Example 1. 0.42 g (1.60 mmol) 7 chloro-6-fluoro-1,4-dihydromethylamino-4 oxo-quinoline-3-carboxylic acid,

s
31551248
0.60 g (4.8 mmol) of 8-methyl 3,8-diazabicyclo (3.2.1) octane and 1 ml of dimethyl sulfoxide (DMSO) are stirred for 3 hours at 140 ° C. After cooling 5, the precipitated crystals are filtered off with suction, washed with ether and crystallized from 2N hydrochloric acid. Hydrochloride 1, 4-dihydro-6 fluoro-1-methyl-amino-7 (8-methyl 3 8-diababi cyclo 3, 1 o 2.1 oct-3 yl) -4-oxo-quinolin-3 carboxy is obtained. - new acid in the form of yellowish crystals with so pl. 291 - 294 ° С (with decomposition) Yield 0.2 | j g (43%).
Example 2: 0.5 g (1.4 mmol) J5 of anhydride 6, / - difluoro-1 - (4-fluorophenyl) -1, 4-dihydro-4-oxo-quinoline-3 carboxylic acid New acid with difluoroboric acid obtained by heating for one hour b, 7-difluoro-1- (4-fluorophenyl) -1,4-dihyd-20 ro-4-oxo-quinoline-3-carboxylic acid with boron trifluoride eterate in acetonitrile obtained after distillation
volatile components, and 0, g (2.0 mmol) of 8-methyl-3 8-diazabicyc-25 lo (3.2.1) -octane dihydrochloride is stirred in 20 ml of absolute DMSO with 0.60 g (6.0 mmol) of triethylamine for 2k hours at 40 ° C. It is then evaporated in vacuo to dry and the residue is heated together with ZO 3.0 ml of 1N NaOH for 1 hour under reflux. After the addition of activated carbon, it is filtered, the filtrate is acidified with 2N hydrochloric acid. The precipitate formed is filtered off and crystallized from a water-dimethylformamide mixture. 0.28 g of 6-fluoro-1- (4-fluorophenyl) -1,4-dihydro-y- (8-methyl-3,8-diazabicyclo 3.2.1-OCT 3 IL) -4-OXO are obtained. -CHINOLIN-3 CarbON-dd
howl acid in the form of colorless crystals with so pl. 280 C (decomposition). The output of 0.27 g (40% of theoretical).
EXAMPLE 3 As in Example 2, however, with 0, .19 g (1.68 mmol) of 2-methyl-2.5-diazabicyclo 2. heptane as starting material, 0.25 g of hydrochloride is obtained. 6-fluoro-1- (4- -fluorophenyl) -1, 4-di hydr o-} - (5 methyl-2,
5-diazabicyclo 2.2.1 hept-2-yl) -4-ok-5o to-quinoline-3-carboxylic acid in vi-1 de colorless crystals. M.p. 26jj ° C (decomposition). The output of 0.48 g (56% of theoretical).
PRI me R 4. To a solution of 1.5 g of its (k mmol) mixed anhydride 6, fluoro-1 - (- fluorophenyl) -CH, 4-dihydro-ox-with-quinoline-3 carboxylic acid and difluoroboron 0.9 g (78 mmol 2- (phenylmethyl) -2.5 diazabicyclo 2.2. 1 heptane and 0, g (mmol) triethylamine) are added to 10 ml of dimethyl sulfoxide and mixed with kth at room temperature. Then the reaction solution diluted with 150 ml of ether. The precipitate formed is filtered off, dispersed in a mixture of 60 ml of dioxane and 9) ml of 1.5 N NaOH solution and heated for 1 hour at 100 ° C. The solution is filtered to remove undissolved material. Then neutralized with concentrated hydrochloric acid. The precipitate is filtered off, washed with distilled water and dried in air. 1.23 g of 6-fluoro-1- (4-fluorophenyl) -1,4-dihydro-4-oxo-7- (5 Phenylmethyl-2,5-diazabicyclo C2.2.1 hept-2-yl are obtained. ) quinoline-3-carboxylic acid. M.p. 275 - 28l) ° C (from DMSO) during decomposition. The output of 1.23 g (63% of theoretical).
Example5. V, OUg (2.2 mmol) 6-fluoro-1- (4-fluorophenyl) -1,4-dihydro-4-oxo-y- (2-phenylmethyl-2,5-diaza-bicyclic 2.2. 1 hept-2-yl) -quinolin-3 carboxylic acid is dissolved in 70 ml of absolute ethanol containing 7 g of hydrochloric acid. 1 g of hydrogenation catalyst (powdered activated carbon with 10% palladium) is added, and the resulting mixture is hydrogenated at 15 psi and 60 ° C for 90 minutes. The catalyst is filtered and the filtrate is evaporated from the mixture on a rotor and again placed in 30 ml of 1 N NaOH solution. The suspended precipitate is filtered off and the aqueous solution is neutralized by addition of concentrated hydrochloric acid. After adding 50 ml of dimethylformamide, the solution is heated to 100 ° C until the gel product is again dissolved. After cooling, a crystalline precipitate of 0.68 g 7 (2,5-diazabicyclo 2. 2,1 hept-2-yl) -6-fluoro-1- (4-fluorophenyl) -1,4-dihydro-4- oxo 3-quinoline-carboxylic acid as monohydrate, t „pl. 290 - 309 ° С (decomposition). Output: 0,69 g (7.4% of theoretical)
PRI me R 6. To 1.2 g (3 mmol) 7 (2,5-Diazabicyclo 2.2.1 hept-6-fluoro -1- (4-fluorophenyl) -1,4-dihydro-4-oxo - quinoline 3 carboxylic acid in 10 ml of formic acid was added 2.64 g (30 mmol) of mixed anhydride from acetic and formic acid. The mixture was stirred for 6 h, then evaporated and
the precipitate is crystallized from ethanol. 0.4 g of 7 (5 formyl--2,5-diazabicyclo G.2.2.1 hept-2-yl) -6-fluoro-1- (4-fluorophenyl) -1,4-dihydro-4-ca-quinolin 3 is obtained. car (young acid, mp. 27k - 276 ° C. Yield 0.4 g (31% of theoretical).
Example: 15.0 g (37.3 mmol of mixed anhydride) Chloro-b-fluoro- (2,4-difluorophenyl) -1,4-dihydro-4-ox-so-quinoline-3-carboxylic acid and diboroboric acid obtained by heating 7 chloro-6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-4-oxo-hino lin-3-carboxylic acid in 60% - fluoroboric acid, 15.36 g (56 mmol) of dihydrobromide, 2-methyl-2.5 Diazabicyclo 2.2.11 heptane, and 31 ml (0.224 mmol) of triethylamine — are added to 200 ml of dry dimethyl sulfoxide and stirred 6 days at room temperature. Then the reaction mixture is poured into 800 ml of cold water. The precipitate formed is filtered off, washed with water and then heated in a mixture of 10 ml of dioxane and 150 ml of 3 N-soda base for 1 hour at reflux. After cooling, 500 ml of concentrated hydrochloric acid is added with stirring. For 1 hour, the insoluble portion is filtered off and the yellow filtrate is extracted several times with methylene chloride. The aqueous phase is cooled to ice with ice-cooling with solid sodium hydroxide, followed by extraction with chloroform.
-
) -
on and 5 ml of dry dimethyl sulfoxide, 2.73 g of 6-fluoro-1- (2,4-difluorophenyl) -1, 4-dihydro-4-oxo-7- (5 Phenylmethyl-2, 5-Ana3a6niiHKnof2.2.1 -hept -2-yl) -3-quinolinecarboxylic acid. M.p. 233 238 ° C (decomposition) after crystallization from toluene. The yield of 2.73 g (39% of theoretical).
Example 2.57 g (5.08 mmol) of 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-4-oxo-7- (5 phenylmethyl-2.5 diaza-bicyclo 2.2. 1Zhept-2-yl) -quinolin-3 carboxylic acid is dissolved in 170 ml
15 absolute ethanol, containing 18 g of hydrochloric acid, and replacing 2.1 g of 10% activated palladium on carbon. Hydrogenated for 2 hours at 15 psi and 60 ° C. After removal of the catalyst, the mixture was evaporated under reduced pressure. The obtained solid is placed in 80 ml of water and the pH is adjusted to 7. The resulting suspension is heated to 60 ° C for 20 minutes. After cooling, the precipitate is filtered off. After crystallization from dimethylformamide, 1.53 g of 7- (2,5-diazabicyclo 2.2.1 hept-2-yl) -6-fluoro-1- (2,4-difluorophenyl) -1,4-di-hydro- 4-oxo-quinoline-3 carboxylic acid as a hydrate. M.p. 198-204 C (decomposition). The yield of 1.53 g (69.5% of theoretical).
Example 10. 0.5 g (1.2 mmol) 7 (2.5 Diazabicyclo 2.2.1 Zhept-2-yl) -6-fluoro-1- (2,4-difluorophenyl) -1,4-di-hydro -4-oxo-quinoline 3 carboxylic acid is suspended in 20 ml of dimethylformamide and replaced with 3 ml of mixed anhydride from acetic and formic acid 25
thirty
35
The chloroform phase is dried with sulphate nat-4Q lot. After stirring for 90 minutes while the mixture is chloroform and chloroform, the solvent is filtered at room temperature. The dark-brown oil thus obtained is distilled off under reduced davoil after crystallization. The oily residue after transferring from 450 ml of ethanol to 3.15 mixing with ether becomes solid 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihyd 4g smoke and can be filtered. Cris - -,. (, -., -C., Pallization from a mixture of 20 ml of dimethylformamide and 5 ml of ligroin gives 0.24 g 7 (5 Formyl-2,5-Diazabicyclo 2.2.1 hept-2-yl) - 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-4-oxo-quinoline-3-carboxylic acid, mp 252 - 258 ° С
(5 methyl-2,5-diazabicyclo 2.2.1J hept-2-yl) -4-oxo-quinolin-3 carboxylic acid as a hydrate. M.p. 215-220 ° C (decomposition). The output of 3.15 g (18.8% of theoretical).
Try on Analogously to Example 6, using g (13.85 mmol) of mixed chloro-6-fluoro-1 - (2,4-difluorophenyl) -1, 4-dihydro-4-oxo-quinoline-3 carboxylic acid and difluoroboric acid anhydride 7 (13.85 mmol) , g (16.62 mmol) 2- (phenylmethyl) -2, azabicyclo .2.1 heptane dihydrobromide, 11.58 ml (83 mmol) with triethylamine50
(decomposition). The output of 0.24 g (45.3% of theoretical).
Example 11. To a solution of 0.6 g 5 (1.5 mmol) 7 (2,5-Diazabicyclo 2.2. 13-hept-2-yl) -6-fluoro-1- (4-fluorophenyl) - -1 , 4-dihydro-4-oxo-quinoline-3 carboxylic acid in 60 ml of dimethylformamide was added 0.23 g (1.65 mmol)
4Q 4g
50
(decomposition). The output of 0.24 g (45.3% of theoretical).
Example 11. To a solution of 0.6 g (1.5 mmol) 7 (2,5-Diazabicyclo 2.2. 13-hept-2-yl) -6-fluoro-1- (4-fluorophenyl) -1, 4-dihydro-4-oxo-quinolin-3 carboxylic acid in 60 ml of dimethylformamide was added 0.23 g (1.65 mmol)
potassium carbonate and 0.82 g (6 mmol) of bromoacetone and the reaction mixture is stirred for 6 hours at room temperature. Then, the excess bromoacetone and dimethylformamide are separated under reduced pressure, the residue is placed in 1 N NaOH, filtered and the pH of the filter is adjusted to 4 6.5 with hydrochloric acid. The resulting residue is filtered, placed in methanol and chromatographed over silica gel (benzene: methanol solvent 5: 4). 0.20 g of 7- (tonyl-2,5-diazabicyclo 2.2.13-hept-2-yl) -6-fluoro-1- (4-fluorophenyl) -1,4-di-hydro-4-oxo is obtained. -quinolin-3-carboxylic acid. M.p. 20U - 205 ° С (decomposition). Yield 0.20 g (29.4% of theoretical).
PRI me R 12. 188 mg (0.434 mmol) of monohydrate 7 (2.5 Diazabicyclo 2.2. O-hept-2-yl) -6-fluoro-1 (2,4-difluorophenyl) -1.4 -dihydro-4-oxo-quinolin-3-carboxylic acid (Example 9) is suspended in 20 ml of dry dimethylformamide, decomposed with 96 mg (0.85 mmol) of anhydrous potassium bicarbonate and, 92 mg (0.48 mmol) 4 bromine -methyl-5 methyl-1, 3-Dioxolen-2-one and stirred for 10 hours at room temperature. Then you-
Strepc.
pneumonia1
Aeinetobaccer
calcoauecicus
Baeteroidfs
Јragilis
Escherichia.
coli
Branharaella
cacarrhalis
Klebsiella
spp,
Scaphylococcus
aureus
Scaphylococcus
epidermidis
Scaphylococcus
spp.
Enterobacuer
0
Pour into a mixture of 150 ml of ethyl acetate and 50 ml of water and separate the phases. The organic phase is washed five times with 30 ml of water, dried over sodium sulfate, filtered and concentrated under reduced pressure at room temperature. Recrystallization from ethyl acetate gives 63 mg of 1- (2,4-difluorophenyl) -6-fluoro-1,4-dihydro-7- (5 C (5-methyl-2-oxo-1, 3-di-salt-4-yl ) methylJ-2,5 Diazabicyclo 2.2 13 hept-2-yl} -4-oxo quinoline-3-carboxylic acid, mp 133 138 ° C (decomposition) .Oil 63 mg (27.5% of theoretical) .
Determination of antibacterial properties in vitro.
The antibacterial properties of the compound of example 7 (compound A) were determined in the OLS-test (minimal test of slowing down concentration) by the agar-dilution method with respect to various gram-positive and anaerobic bacteria strains and compared with the structural analogue 6-fluoro-1- (4-fluoride - nyl) -1,4-dihydro-7- (5-methyl-2, 5-diazabits | f "l-2.2.1 hept-2-yl) -4-oxo-3 quinoline carboxylic acid ( compound B). The results are placed in the table. one.
Table 1
0.25 1, OS 0.06 0.12 2.00 4.00 0.03 0.12
less than 0.015 0.03
L,), 06 0.06 0.12 0.12 0.12 0.25 0.25 0.50 0.12
0.50 1.00 0.25 0.50 2.00 4.00 0.06 0.12
oh oz oz oz
0.06 0.12 0.12 0.12 0.25 0.25 9.25 0.50 0.12
0.50 2.00 2.00 4.00 2.00 4.00 0.06 0.12
0.03 0.06 0.12 0.25 0.12 0.25 0.25 0.25 0.50 0.50 0.50
Determination of antibacterial properties in vitro.
The antibacterial properties of the compounds of examples 7 and 9 were determined in the OLS-test (the minimum test concentration of Escherichia coli
Klebsiella pneumoniae
n
Klbbsiella pneumo- niae
Encerobaccer cloacae
to
it
Serracia marcescens ii
15512W
Continued table. one
deceleration radios using the agar-dilution method, Müller-Ginton medium, in relation to various gram-positive and gram-negative bacterial strains and compared with pefloxazine. The results are presented in table. 2
table 2
0,120
0.060
0,250
eleven
$ 5 2kQ12
i, Continued tA. 2
As can be seen from the gab. 1 and 2, the proposed compounds are superior to known structural analogues for their antibacterial action against various bacterial strains.
Tests on rats of the compound of Example 7 showed that the compounds fall into the low toxic category.

权利要求:
Claims (2)
[1]
1. Method of producing -pyridone derivatives of general formula I
F JLCOOX
N
i
Ri
where K, is 2,4-difluorophenyl; X is hydrogen; Y is the basis of General formula II
Rf $ N where Ra is hydrogen, lower alkyl, form 55 kg is lower alkyl or protective
mil or acetonyl, amino, in an inert solvent,
or them. Pharmaceutically acceptable, such as dimethylformamide or dimeadditive salts with inorganic methyl sulfoxide, combined with organic acids or basic-of-formula 1a
vanes, or their hydrates, characterized in that the compound of general formula III
ABOUT
gglcooks i / 4Ai
i
where K L
R.
has the indicated value; nucleophilic leaving group, such as chlorine or fluorine;
hydrogen, lower alkyl, or boric complex — B (R4R5), where R and R5 are the same and represent fluorine or the residue —0 (CO) — lower alkyl, is reacted with a compound of general formula IV
) N-H
where K1, RJ have the indicated meanings; Y is the radical of General formula IVa
where R 2 has the indicated meanings; or in the case when RJ is lower alkyl or group B (R4R), compound 1a is converted into compound I by the action of aqueous alkali or organic base, where X is hydrogen;
ten
15 2481
or, in the case of a protective group in compound 1a in the R2 position, it is cleaved off;
or, if necessary, the obtained compound of formula I, where R2 is hydrogen, is methylated, formulated, or substituted with bromoacetone to isolate the target product in free form or in the form of pharmaceutically acceptable addition salts with an acid or base, or their hydrates.
[2]
2. The method according to claim. Wherein the reaction of the compound of the general formula IV, where R3 is B (.), R4 and R takes the indicated values, with the compound of the formula V is carried out at a temperature from room temperature to 50 ° C for 1-30 h

类似技术:

公开号 | 公开日 | 专利标题

SU1482531A3|1989-05-23|Method of producing substituted diazobycycloalkyloquinolone carbolic acids with bridge bonds or their pharmaceutically acceptable additive salts

US4665079A|1987-05-12|Antibacterial agents

SU1551248A3|1990-03-15|Method of producing 4-pyridon-derivatives or their pharmaceutically aceeptable additive salts with inorganic or organic acids or bases, or their hydrates

EP0266576A2|1988-05-11|1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents

US4777175A|1988-10-11|Antibacterial agents

US5091384A|1992-02-25|Anti-bacterial quinolone- and naphthyridone-carboxylic acid compounds

US4657913A|1987-04-14|Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents

US4954507A|1990-09-04|1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents

AU611400B2|1991-06-13|1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents

US5688965A|1997-11-18|Azabicyclic compounds useful as an intermediate for the preparation of pyidone carboxylic acid compounds and process for preparing the same

EP0387802A2|1990-09-19|5-Substituted-1,4-dihydro-4-oxonaphthyridine-3-carboxylate antibacterial agents

US4617308A|1986-10-14|7-substituted amino-1-aryl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and derivatives thereof as antibacterial agents

WO1994025464A1|1994-11-10|Novel quinolone carboxylic acid derivatives and process for preparing the same

Toja et al.1986|Pyrrolopyridine analogs of nalidixic acid. 1. Pyrrolo [2, 3‐b] pyridines

US4923879A|1990-05-08|1,8-Naphthyridines and their use as antibacterial agents

US4965273A|1990-10-23|Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents

US5990106A|1999-11-23|Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof

EP0200307B1|1989-12-20|Improved process for production of quinoline-3-carboxylic acid antibacterial agents

US4962108A|1990-10-09|Antibacterial quinoline compounds

FI70219C|1986-09-15|PROCEDURE FOR THE FRAMSTATION OF BETA-LACTAMANT BIOOTICS

EP0216323A2|1987-04-01|Quinolonecarboxylic acid derivatives and their preparation

US6017911A|2000-01-25|Pyridonecarboxylic acid derivatives and intermediates for the synthesis thereof

DE3721745A1|1988-01-14|Bicyclically substituted quinolonecarboxylic acid derivatives, process for their preparation, and pharmaceutical preparations containing these

US4968799A|1990-11-06|Antibacterial agents

EP0221541A2|1987-05-13|Quinolonecarboxylic acid derivatives and their preparation

同族专利:

公开号 | 公开日

YU45039B|1991-06-30|

DK342187A|1988-01-05|

DE3766299D1|1991-01-03|

EP0251308B1|1990-11-22|

EP0251308A1|1988-01-07|

AT58538T|1990-12-15|

DK342187D0|1987-07-03|

YU124687A|1988-12-31|

JPS6322580A|1988-01-30|

FI872897A|1988-01-05|

HU197907B|1989-06-28|

ES2018667B3|1991-05-01|

NZ220950A|1990-07-26|

KR880001595A|1988-04-25|

NO872778D0|1987-07-02|

NO166130B|1991-02-25|

IL83049D0|1987-12-31|

GR3001097T3|1992-04-17|

IL83049A|1991-12-12|

AU7508087A|1988-01-07|

CS505587A3|1992-08-12|

HUT45060A|1988-05-30|

PT85257A|1987-08-01|

NO872778L|1988-01-05|

FI88506C|1993-05-25|

NO166130C|1991-06-05|

US5045549A|1991-09-03|

FI88506B|1993-02-15|

ZA874849B|1988-03-30|

AU608515B2|1991-04-11|

CS277415B6|1993-03-17|

PH24239A|1990-05-04|

AR245450A1|1994-01-31|

DD262428A1|1988-11-30|

JPH07103123B2|1995-11-08|

PT85257B|1990-03-30|

MY101261A|1991-08-17|

FI872897A0|1987-07-01|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

CA1175836A|1977-09-20|1984-10-09|Marcel Pesson|Production of 1,4-dihydroquinoline-3-carboxylicacid derivatives|

DE2808070A1|1978-02-24|1979-08-30|Bayer Ag|PROCESS FOR THE PRODUCTION OF 4-PYRIDONE-3-CARBONIC ACIDS AND / OR DERIVATIVES|

DE3267485D1|1981-02-18|1986-01-02|Nippon Shinyaku Co Ltd|Substituted carboxylic acid derivatives|

EP0090424B1|1982-03-31|1986-05-28|Sterling Drug Inc.|New quinolone compounds and preparation thereof|

US4499091A|1982-03-31|1985-02-12|Sterling Drug Inc.|1-Amino -1,4-dihydro-4-oxo-6-fluoro-7-heterylquinoline-3-carboxylic acids and their use as antibacterial agents|

NZ208470A|1983-07-18|1988-06-30|Abbott Lab|6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such|

JPH0146512B2|1983-07-18|1989-10-09|Abbott Lab|

US4730000A|1984-04-09|1988-03-08|Abbott Laboratories|Quinoline antibacterial compounds|

US4571396A|1984-04-16|1986-02-18|Warner-Lambert Company|Antibacterial agents|

EP0181521A1|1984-10-19|1986-05-21|Otsuka Pharmaceutical Co., Ltd.|Antimicrobial 1-substituted Phenyl-4-oxoquinoline-3-carboxylic acid compounds|

US4578473A|1985-04-15|1986-03-25|Warner-Lambert Company|Process for quinoline-3-carboxylic acid antibacterial agents|

IN166416B|1985-09-18|1990-05-05|Pfizer|

DE3601567A1|1986-01-21|1987-07-23|Bayer Ag|7- -CHINOLONCARBONIC ACID AND -NAPHTHYRIDON-CARBONIC ACID DERIVATIVES|

US4923879A|1987-07-31|1990-05-08|Warner-Lambert Company|1,8-Naphthyridines and their use as antibacterial agents|

US4962108A|1987-07-31|1990-10-09|Warner-Lambert Company|Antibacterial quinoline compounds|

US4962112A|1987-08-04|1990-10-09|Abbott Laboratories|7-naphthryidine and quinoline compounds|

US4780468A|1987-08-07|1988-10-25|Warner-Lambert Company|8-trifluoromethyl quinolones as antibacterial agents|

US4851418A|1987-08-21|1989-07-25|Warner-Lambert Company|Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent|

WO1989005643A1|1987-12-18|1989-06-29|Pfizer Inc.|Heterocyclic-substituted quinoline-carboxylic acids|

US4920120A|1988-01-25|1990-04-24|Warner-Lambert Company|Antibacterial agents|IN166416B|1985-09-18|1990-05-05|Pfizer|

SI8810667A8|1987-04-08|1996-04-30|Chinoin Gyogyszer Es Vegyeszet|Anhydride of quinoline carboxylic acid of boron acid and process for their production.|

WO1989012055A1|1988-06-08|1989-12-14|Kyorin Pharmaceutical Co., Ltd.|Antitumor agent|

EP0449445A3|1990-03-27|1993-08-25|Pfizer Inc.|Preparation of beta-ketoesters useful in preparing quinolone antibiotics|

EP0525057B1|1990-04-18|2000-06-14|Procter & Gamble Pharmaceuticals, Inc.|Antimicrobial quinolonyl lactams|

FR2692577B1|1992-05-26|1996-02-02|Bouchara Sa|NOVEL FLUORINATED QUINOLONES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|

TW252107B|1993-08-27|1995-07-21|Hokuriku Pharmacetical Co Ltd|

ES2092963B1|1995-04-12|1997-12-16|Sint Quimica Sa|PROCEDURE FOR THE PREPARATION OF ACID 1-CICLOPROPIL-6-FLUORO-1, 4-DIHIDRO-7--5-METHYL-2,5-DIAZABICICLOHEPT-2-IL) -4 -OXO-3-QUINOLINCARBOXILICO AND ITS SALTS.|

SE0003795D0|2000-10-20|2000-10-20|Astrazeneca Ab|Pharmaceutically useful compounds|

WO2011031745A1|2009-09-09|2011-03-17|Achaogen, Inc.|Antibacterial fluoroquinolone analogs|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

DE3622509|1986-07-04|

[返回顶部]